Abstract
Background
Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin's lymphoma in the United States, with approximately 40% of first-line DLBCL chemoimmunotherapy attempts failing. The FDA approved a new type of antibody–drug conjugate (ADC), Zynlonta (loncastuximab tesirine), once called ADCT-402, on April 23, 2021, for relapsed or refractory (R/R) DLBCL. Loncastuximab tesirine comprises a humanized anti-CD19 monoclonal antibody conjugated to a pyrrolobenzodiazepine dimer toxin.
Purpose
The purpose of this article is to review the pharmacological properties of loncastuximab tesirine and evaluate its efficacy and safety in the treatment of R/R DLBCL.
Methods
In PubMed, Web of Science and CNKI, I searched for relevant literature as of November 2021 through some keywords. Obtained loncastuximab tesirine essential drug and related clinical trial information on https://www.adctherapeutics.com/ and clinicaltrials.gov.
Results
Once it binds with cells expressing CD19, loncastuximab tesirine is internalized by the cell and then releases SG3199, which irreversibly binds to the DNA, thereby disrupting the basic DNA metabolism process and ultimately leading to cell death. The results of the main non-comparative clinical trials LOTIS-1, LOTIS-2 and LOTIS-3 were encouraging. In LOTIS-1, the overall response rate (ORR) of R/R DLBCL patients treated with loncastuximab tesirine was 42.3%, and loncastuximab tesirine had excellent stability and acceptable safety profile. The recommended dosage of loncastuximab tesirine is 0.15 mg/kg every three weeks for two cycles, 0.075 mg/kg every three weeks for each subsequent cycle. The pivotal LOTIS-2 showed that loncastuximab tesirine had substantial single-agent antitumour activity in patients with R/R DLBCL: the ORR and complete response rate were 48.3% and 24.1%, respectively, and produced a durable response with acceptable safety and tolerability. The results of the LOTIS-3 phase 1 portion indicated that loncastuximab tesirine 60 µg/kg plus ibrutinib 560 mg had encouraging antitumour activity in R/R DLBCL, with an ORR of 56.7%. Haematological adverse events such as anaemia and neutropenia, non-haematological events such as fatigue and nausea, and biochemical events such as γ-glutamyl transferase increase, and blood alkaline phosphatase increases were common after administration of loncastuximab tesirine.
Conclusions
Loncastuximab tesirine is a CD19-targeted ADC that addresses the unmet needs of R/R DLBCL patients who have been heavily pretreated, comprising high-risk populations.
Similar content being viewed by others
Data availability
Not applicable.
Code availability
Not applicable.
References
Zammarchi F, Corbett S, Adams L et al (2018) ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 131(10):1094–1105
Jain N, Stock W, Zeidan A et al (2020) Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv 4(3):449–457
Hamadani M, Radford J, Carlo-Stella C et al (2021) Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 137(19):2634–2645
Kahl BS, Hamadani M, Radford J et al (2019) A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res 25(23):6986–6994
American Cancer Society (2021) Types of B-cell Lymphoma. Available at: https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/b-cell-lymphoma.html. Accessed June 2021
Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116:2040–2045
Crump M, Neelapu SS, Farooq U et al (2018-2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood 131(5):587–588]. Blood 130(16):1800–1808
Hartley JA (2021) Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin Biol Ther 21(7):931–943
Chu Y, Zhou X, Wang X (2021) Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol Oncol 14(1):88
ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma. https://ir.adctherapeutics.com/press-releases/press-release-details/2020/ADC-Therapeutics-Submits-Biologics-License-Application-to-the-U.S.-Food-and-Drug-Administration-for-Loncastuximab-Tesirine-for-Treatment-of-Relapsed-or-Refractory-Diffuse-Large-B-cell-Lymphoma/default.aspx
FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-loncastuximab-tesirine-lpyl-large-b-cell-lymphoma
Caimi PF, Ai W, Alderuccio JP et al (2021) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 22(6):790–800
Mullard A (2021) FDA approves ADC Therapeutics’ loncastuximab tesirine, ushering in a new cytotoxic payload. Nat Rev Drug Discov 20(6):414
Zynlonta™ Press Releases. ADC Therapeutics SA. https://ir.adctherapeutics.com/press-releases/default.aspx
Zynlonta™ Prescribing Information. ADC Therapeutics SA. https://www.adctherapeutics.com/wp-content/uploads/2021/04/pi.pdf
Tarantelli C et al (2019) "The antibody-drug conjugate (ADC) loncastuximab tesirine (ADCT-402) targeting CD19 shows strong in vitro anti-lymphoma activity both as single agents and in combination." Hematological Oncology 37: 129–130.
Depaus J et al (2021) "Clinical activity of loncastuximab tesirine plus ibrutinib in non‐hodgkin lymphoma: Updated lotis 3 phase 1 results." Hematologi Oncol 39
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma. https://clinicaltrials.gov/ct2/show/NCT03684694
Zinzani, PL et al (2021) "Lotis 2 follow-up analysis: Updated results from a phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large b-cell lymphoma." Hematol Oncol 39 (2021)
Caimi, Paolo F et al (2020) "Efficacy and safety of loncastuximab tesirine (ADCT-402) in relapsed/refractory diffuse large B-cell lymphoma." Blood 136(Suppl 1):35–37
Thapa B, Caimi PF, Ardeshna KM et al (2020) CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy [published correction appears in Blood Adv 4(19):4606]. Blood Adv 4(16):3850–3852
Spira A, Zhou X, Chen L et al (2021) Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [published online ahead of print, 2021 Sep 22]. Clin Lymphoma Myeloma Leuk S2152–2650(21)02031–0
Alderuccio JP et al (2021) "ABCL–396: Incidence, Onset, and Management of Edema and Effusion in Patients Treated with Loncastuximab Tesirine for R/R DLBCL in the LOTIS Clinical Trial Program." Clin Lymphoma Myeloma Leuk 21:S397–S398
Solh Melhem et al (2021) "ABCL–362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R/R DLBCL in a Pooled Safety Analysis." Clin Lymphoma Myeloma Leuk 21: S394–S395
Sorensen EP, Thrush J, Bartlett NL, Rosman IS, Anadkat MJ, Jones HA (2020) Diffuse Telangiectatic Rash Associated With Novel Antibody Drug Conjugate Therapies. JAMA Dermatol 156(5):601–603
Drugs and Lactation Database (LactMed) (2021). Bethesda (MD): National Library of Medicine (US); 2006–. Loncastuximab Tesirine
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5) https://clinicaltrials.gov/ct2/show/NCT04384484
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS 6). https://clinicaltrials.gov/ct2/show/NCT04699461
Liao L et al (2021) "Treatment-Related Costs of Pharmacologic Regimens for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Who Have Received Two or More Prior Lines of Therapies." Value in health. Vol. 24. STE 800, 230 Park Ave, New York, NY 10169 USA: Elsevier Science INC.,
Zynlonta Prices, Coupons and Patient Assistance Programs. https://www.drugs.com/price-guide/zynlonta
Carlo-Stella C et al (2019) "Interim futility analysis of a phase 2 study of loncastuximab tesirine, a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in patients with relapsed or refractory diffuse large B-cell lymphoma." Blood 134(Suppl 1): 757
Hamadani M et al (2021) "Phase 3 Randomized Study of Loncastuximab Tesirine plus Rituximab versus Immunochemotherapy in Patients with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)—LOTIS-5." TPS7574-TPS7574
Funding
Not applicable.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
Not applicable.
Conflicts of interest
Bo Xu declare that he has no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xu, B. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma. Eur J Clin Pharmacol 78, 707–719 (2022). https://doi.org/10.1007/s00228-021-03253-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-021-03253-3